Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug Incentives Would Go Further Than Regulatory Reform - Reardan

Executive Summary

Eleos VP-Regulatory Affairs Dayton Reardan suggested that instead of focusing on problems with FDA's review process for rare disease drugs, government should create more development incentives in order to bring more drugs for rare diseases to market
Advertisement

Related Content

Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Topics

Advertisement
UsernamePublicRestriction

Register

PS052399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel